Right Ventricular Bone-Avid Tracer Uptake: A Novel Risk Marker in Transthyretin Amyloid Cardiomyopathy.
作者信息
Dorbala Sharmila
机构信息
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Cardiac Amyloidosis Program, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
出版信息
Circulation. 2024 Apr 9;149(15):1169-1171. doi: 10.1161/CIRCULATIONAHA.124.067985. Epub 2024 Apr 8.
Abstract
摘要
相似文献
1
Right Ventricular Bone-Avid Tracer Uptake: A Novel Risk Marker in Transthyretin Amyloid Cardiomyopathy.右心室骨亲和性示踪剂摄取：转甲状腺素蛋白淀粉样心肌病的一种新型风险标志物。
Circulation. 2024 Apr 9;149(15):1169-1171. doi: 10.1161/CIRCULATIONAHA.124.067985. Epub 2024 Apr 8.
2
Clinical and Prognostic Implications of Right Ventricular Uptake on Bone Scintigraphy in Transthyretin Amyloid Cardiomyopathy.转甲状腺素蛋白淀粉样心肌病中右心室摄取骨闪烁显像的临床和预后意义。
Circulation. 2024 Apr 9;149(15):1157-1168. doi: 10.1161/CIRCULATIONAHA.123.066524. Epub 2024 Feb 8.
3
Expanding the role of bone-avid tracer cardiac single-photon emission computed tomography/ computed tomography: assessment of treatment response in transthyretin amyloid cardiomyopathy.
Eur Heart J Cardiovasc Imaging. 2023 Jul 24;24(8):1031-1032. doi: 10.1093/ehjci/jead108.
4
Current Status of Radionuclide Imaging of Transthyretin Cardiac Amyloidosis.转甲状腺素蛋白心脏淀粉样变性的放射性核素成像现状。
Cardiol Clin. 2023 May;41(2):217-231. doi: 10.1016/j.ccl.2023.01.010. Epub 2023 Feb 23.
5
Early Detection of Transthyretin Cardiac Amyloidosis Using I-Evuzamitide Positron Emission Tomography/Computed Tomography.使用I-Evuzamitide正电子发射断层扫描/计算机断层扫描早期检测转甲状腺素蛋白心脏淀粉样变性
JACC Cardiovasc Imaging. 2025 Jul;18(7):799-811. doi: 10.1016/j.jcmg.2025.01.018. Epub 2025 May 28.
6
Current Status of Radionuclide Imaging of Transthyretin Cardiac Amyloidosis.转甲状腺素蛋白心脏淀粉样变的放射性核素成像现状
Heart Fail Clin. 2025 Jul;21(3):427-441. doi: 10.1016/j.hfc.2025.01.009.
7
Gene Silencing Therapy in Hereditary (Variant) Transthyretin Cardiac Amyloidosis: A Puzzling Case of Decreasing Pyrophosphate Uptake on Scintigraphy.遗传性（变异型）转甲状腺素蛋白心脏淀粉样变性的基因沉默治疗：一例骨闪烁显像中焦磷酸盐摄取减少的疑难病例
Circ Cardiovasc Imaging. 2023 Aug;16(8):e015243. doi: 10.1161/CIRCIMAGING.123.015243. Epub 2023 Jun 19.
8
Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis.(99m)Tc-DPD 闪烁显像在遗传性转甲状腺素蛋白相关心脏淀粉样变性的诊断和预后中的作用。
JACC Cardiovasc Imaging. 2011 Jun;4(6):659-70. doi: 10.1016/j.jcmg.2011.03.016.
9
Deep learning approach for automated segmentation of myocardium using bone scintigraphy single-photon emission computed tomography/computed tomography in patients with suspected cardiac amyloidosis.深度学习方法在疑似心脏淀粉样变性患者的骨闪烁单光子发射计算机断层扫描/计算机断层扫描中自动分割心肌的应用。
J Nucl Cardiol. 2024 Mar;33:101809. doi: 10.1016/j.nuclcard.2024.101809. Epub 2024 Feb 1.
10
Effects of Vutrisiran on Cardiac Function and Outcomes in Patients With Transthyretin Amyloidosis With Cardiomyopathy.维特西瑞对转甲状腺素蛋白淀粉样变心肌病患者心脏功能及预后的影响
J Am Coll Cardiol. 2025 Aug 12;86(6):444-455. doi: 10.1016/j.jacc.2025.06.022.
本文引用的文献
1
Clinical and Prognostic Implications of Right Ventricular Uptake on Bone Scintigraphy in Transthyretin Amyloid Cardiomyopathy.转甲状腺素蛋白淀粉样心肌病中右心室摄取骨闪烁显像的临床和预后意义。
Circulation. 2024 Apr 9;149(15):1157-1168. doi: 10.1161/CIRCULATIONAHA.123.066524. Epub 2024 Feb 8.
2
Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy.转甲状腺素蛋白介导的遗传性神经病淀粉样变患者中 vutrisiran 对探索性心脏参数的影响。
Eur J Heart Fail. 2024 Feb;26(2):397-410. doi: 10.1002/ejhf.3138. Epub 2024 Feb 6.
3
Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy.阿伐曲泊帕在转甲状腺素蛋白淀粉样心肌病中的疗效和安全性。
N Engl J Med. 2024 Jan 11;390(2):132-142. doi: 10.1056/NEJMoa2305434.
4
Quantification of right ventricular amyloid burden with 18F-florbetapir positron emission tomography/computed tomography and its association with right ventricular dysfunction and outcomes in light-chain amyloidosis.用 18F-氟苯丙氨酸正电子发射断层扫描/计算机断层扫描定量检测右心室淀粉样变负荷及其与轻链淀粉样变性患者右心功能障碍和结局的关系。
Eur Heart J Cardiovasc Imaging. 2024 Apr 30;25(5):687-697. doi: 10.1093/ehjci/jead350.
5
Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis.依洛硫酸酯酶治疗遗传性转甲状腺素蛋白淀粉样变性心肌病患者的心脏结构和功能的影响。
J Card Fail. 2024 Aug;30(8):973-980. doi: 10.1016/j.cardfail.2023.11.016. Epub 2023 Dec 7.
6
Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy.依洛硫酸酯酶纳治疗遗传性转甲状腺素蛋白淀粉样变性多发性神经病。
JAMA. 2023 Oct 17;330(15):1448-1458. doi: 10.1001/jama.2023.18688.
7
Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis.心脏淀粉样变性患者的右心室与肺动脉耦合及预后
Eur Heart J Cardiovasc Imaging. 2023 Sep 26;24(10):1405-1414. doi: 10.1093/ehjci/jead145.
8
Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid.抗心肌转甲状腺素蛋白抗体 NI006 用于清除心脏淀粉样变性的 1 期临床试验。
N Engl J Med. 2023 Jul 20;389(3):239-250. doi: 10.1056/NEJMoa2303765. Epub 2023 May 20.
9
Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy.用定量 SPECT/CT 监测转甲状腺素蛋白淀粉样心肌病中的塔法米迪治疗。
Eur Heart J Cardiovasc Imaging. 2023 Jul 24;24(8):1019-1030. doi: 10.1093/ehjci/jead030.
10
Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression.用帕替沙那治疗可降低 CMR 衍生细胞外体积，表明心脏淀粉样变得到了逆转。
JACC Cardiovasc Imaging. 2021 Jan;14(1):189-199. doi: 10.1016/j.jcmg.2020.07.043. Epub 2020 Oct 28.
Zotero 插件